Common-Size Balance Sheet: Assets
Quarterly Data
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Statement of Comprehensive Income
- Analysis of Profitability Ratios
- Enterprise Value (EV)
- Enterprise Value to EBITDA (EV/EBITDA)
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Price to Earnings (P/E) since 2005
- Price to Operating Profit (P/OP) since 2005
- Price to Sales (P/S) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Regeneron Pharmaceuticals Inc., common-size consolidated balance sheet: assets (quarterly data)
Based on: 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31).
The asset composition exhibits a structural transition from a current-asset-heavy balance sheet to one increasingly weighted toward noncurrent assets. Total current assets decreased from a peak of 62.08% in June 2021 to 44.20% by June 2026, while noncurrent assets rose from 43.42% to 55.80% over the same period.
- Liquidity and Cash Management
- A shift in the allocation of liquid assets is evident. Cash and cash equivalents peaked at 14.50% in September 2021 but have since stabilized at lower levels, generally fluctuating between 5% and 8% in more recent periods. Conversely, current marketable securities saw a significant expansion, peaking at 24.53% in September 2023 before retreating to 13.27% by June 2026. Noncurrent marketable securities remained more stable, typically ranging between 16% and 26% of total assets, indicating a strategic preference for diversified liquidity instruments over immediate cash holdings.
- Working Capital Trends
- There is a notable reduction in the weight of accounts receivable, which declined from a high of 32.57% in June 2021 to 15.73% by June 2026. This downward trend suggests an improvement in collection efficiency or a fundamental change in the timing of revenue realization. Inventories have remained remarkably stable, hovering between 7% and 8% for the majority of the observed period, indicating a consistent inventory-to-asset ratio.
- Long-Term Asset Evolution
- Property, plant, and equipment (PP&E) show a gradual long-term decline, moving from 18.36% in March 2021 to 13.08% by June 2026, suggesting that asset growth in other areas is outpacing capital expenditures in physical infrastructure. Intangible assets emerged in late 2022 and have maintained a steady presence around 3% of total assets. A significant upward trend is observed in deferred tax assets, which grew from 4.31% to 10.50%, and other noncurrent assets, which rose from 0.82% to 5.53%, collectively contributing to the increase in total noncurrent assets.